The head of BioNTech assessed the effectiveness of the company's vaccine against the omicron strain

Head of BioNTech ahin: Comirnaty vaccine is probably effective against omicron strain

Head of BioNTech Ugur ahin ), developed by the German company BioNTech (“Biontech”) together with the American partner Pfizer (“Pfizer”), against the new omicron strain of the coronavirus. His words are quoted by Reuters.

Shahin pointed out that the drug is likely to provide protection against severe disease, referring to cases where patients require hospitalization or intensive care. “We believe that humans are likely to have significant protection against the severe course of the omicron strain,” he explained.

Related Materials 00:01 – September 8 ” The lack of vaccines is a shame “The acute phase of a pandemic could drag on for years. How can humanity defeat the coronavirus? 17: 19 – 27 November A new strain of coronavirus from Africa has arrived in Europe. What is known about the omicron and how dangerous it is? doses of the Comirnaty vaccine are able to suppress the new type of coronavirus.

Shahin noted that the third, booster dose of the vaccine will provide sufficient protection compared to those who received only two doses. According to him, there is no reason for concern, but only those patients who are not vaccinated at all cause anxiety.

Earlier, the head of Rospotrebnadzor Anna Popova said that all vaccines against COVID-19 existing in Russia are effective against the omicron strain coronavirus. She added that PCR testing, which is being carried out in Russia, is also capable of identifying a new strain. According to the latest estimates, no omicron-strain of coronavirus has been detected in Russia.

On November 11, a new strain of coronavirus under the code B.1.1.529 was detected in South Africa. The first cases of infection were registered on November 24.



Leave a Reply